We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

European Study of Cardiovascular Risk (EURIKA)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00882336
First Posted: April 16, 2009
Last Update Posted: October 29, 2009
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
AstraZeneca
  Purpose

The main objective of this study is to describe the management of patients with cardiovascular risk factors in primary prevention among different European countries.

The patient's participation consists of a single study visit during a routine visit of the patient to the clinic/office.

Study variables will be measured:

  • By an interview between physician and patient during the visit and/or available medical records' information: social and demographic patient characteristics, relevant family medical history, current medication.
  • By questions asked to the physician: physician perception of patients' CV risk factor, guidelines adherence and cost-containment.
  • By measurement performed to the patient during the visit: weight, height, BMI, waist and hip circumference will be measured.
  • CV risk factors (blood parameters) will be measured by collecting available data documented within the last year in the medical records and by the collection and analyses of a blood sample during the visit.

Condition
Cardiovascular Risk Factors Hyperlipidemia Hypertension Diabetes Obesity Smoking

Study Type: Observational
Study Design: Time Perspective: Cross-Sectional
Official Title: Epidemiological Study of European Cardiovascular Risk Patients: Disease Prevention and Management in Usual Daily Practice

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • LDL-cholesterol, systolic and diastolic blood pressure, Tot. cholesterol, Non-HDL cholesterol, HDL-cholesterol, waist and hip circumference, HbA1c [ Time Frame: Cross-sectional ]
  • Gender, age, patients with diabetes and/or hypertension (%), smoker status, family medical history. [ Time Frame: Cross-sectional ]

Secondary Outcome Measures:
  • BMI, Score based 10 year CHD mortality > 5%, High Risk patients (no. and %) [ Time Frame: Cross-sectional ]
  • Use of concomitant medication: anticoagulant, anti hypertensive, antidiabetic, lipid-lowering drugs [ Time Frame: Cross-sectional ]
  • Biomarkers: Apo-A1, Apo-B, Hs-CRP, Creatinine, albuminuria, uric acid, glomerular filtration rate. [ Time Frame: Cross-sectional ]

Biospecimen Retention:   Samples Without DNA
Whole blood Serum

Estimated Enrollment: 7200
Study Start Date: May 2009
Study Completion Date: October 2009
Groups/Cohorts
1
Patients 50+ years old, with at least one additional CV risk factor (with no previous CV event or hospitalization for a CV event)

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   50 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Patients 50+ years old, with at least one additional CV risk factor (with no previous CV event or hospitalisation for a CV event) from Primary Care or hospital outpatient clinic.Participating investigators will belong either to PC centres or hospitals, in the proportion representing the reality on where this kind of patient is managed in each country.
Criteria

Inclusion Criteria:

  • Provision of informed consent.
  • Patients 50+ years old, with at least one additional CV risk factor (with no previous CV event or hospitalisation for a CV event) from Primary Care or hospital outpatient clinic.

Exclusion Criteria:

  • Subjects who are unwilling or unable to provide informed consent
  • Previous CV disease event or hospitalisation for a CV event
  • Current participation in a clinical trial
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00882336


  Show 778 Study Locations
Sponsors and Collaborators
AstraZeneca
Investigators
Study Director: Elvira Massó AstraZeneca Spain
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Responsible Party: MSD, AstraZeneca
ClinicalTrials.gov Identifier: NCT00882336     History of Changes
Other Study ID Numbers: NIS-CEU-DUM-2008/1
First Submitted: April 15, 2009
First Posted: April 16, 2009
Last Update Posted: October 29, 2009
Last Verified: October 2009

Keywords provided by AstraZeneca:
Cardiovascular risk management
Hyperlipidemia
Hypertension
Diabetes
Obesity

Additional relevant MeSH terms:
Hypertension
Hyperlipidemias
Hyperlipoproteinemias
Vascular Diseases
Cardiovascular Diseases
Dyslipidemias
Lipid Metabolism Disorders
Metabolic Diseases